Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of eye disorders.
Nyxol® Eye Drops is a once-daily preservative-free eye drop formulation designed to reduce pupil size and improve visual acuity.
APX3330 is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammatory pathways relevant to retinal and choroidal vascular diseases.
Ocuphire Pharma plans to initiate a second Phase 3 registration trial in the fourth quarter of 2021.
Sep 3, 2021 5:00pm EDT
Sep 2, 2021 7:00am EDT
Aug 12, 2021 7:00am EDT
Aug 6, 2021 7:30am EDT
Stay informed and receive company updates straight to your inbox.